Northern Trust Corp Has $10.12 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Northern Trust Corp raised its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 12.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 257,168 shares of the company's stock after buying an additional 29,416 shares during the quarter. Northern Trust Corp owned about 0.30% of CRISPR Therapeutics worth $10,122,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Western Pacific Wealth Management LP lifted its stake in CRISPR Therapeutics by 100.0% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after buying an additional 500 shares in the last quarter. Spire Wealth Management lifted its stake in CRISPR Therapeutics by 303.7% in the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company's stock valued at $78,000 after buying an additional 1,482 shares in the last quarter. MCF Advisors LLC bought a new position in CRISPR Therapeutics in the fourth quarter valued at approximately $80,000. First Horizon Advisors Inc. raised its holdings in shares of CRISPR Therapeutics by 33.4% in the fourth quarter. First Horizon Advisors Inc. now owns 2,039 shares of the company's stock valued at $80,000 after purchasing an additional 511 shares during the last quarter. Finally, AdvisorNet Financial Inc raised its holdings in shares of CRISPR Therapeutics by 91.1% in the fourth quarter. AdvisorNet Financial Inc now owns 2,478 shares of the company's stock valued at $98,000 after purchasing an additional 1,181 shares during the last quarter. Institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Stock Performance

CRSP traded down $0.67 during trading on Friday, reaching $36.86. 1,256,881 shares of the stock were exchanged, compared to its average volume of 1,686,719. The stock's 50 day moving average price is $37.05 and its two-hundred day moving average price is $42.00. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $67.88. The stock has a market cap of $3.18 billion, a P/E ratio of -8.43 and a beta of 1.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same quarter in the prior year, the firm earned ($1.43) EPS. CRISPR Therapeutics's revenue was up 71.6% compared to the same quarter last year. Equities research analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director John Greene acquired 7,000 shares of CRISPR Therapeutics stock in a transaction on Wednesday, February 26th. The stock was purchased at an average cost of $44.85 per share, with a total value of $313,950.00. Following the completion of the transaction, the director now directly owns 7,000 shares in the company, valued at $313,950. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 2,850 shares of the company's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the transaction, the general counsel now owns 77,530 shares in the company, valued at $3,288,822.60. This trade represents a 3.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,021 shares of company stock valued at $594,771 over the last ninety days. 4.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Citigroup lowered their price objective on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating on the stock in a report on Tuesday, February 18th. TD Cowen upgraded shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price objective on the stock in a report on Wednesday, February 12th. Truist Financial lifted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a report on Wednesday, February 12th. The Goldman Sachs Group lowered their price objective on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Finally, Evercore ISI upgraded shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and lifted their price objective for the company from $60.00 to $99.00 in a report on Friday, February 14th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $71.75.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.